Soft Tissue Sarcoma market

Mar 20, 2020

Comprising less than 1% of all the adult malignancies, and inflicting pain in more than one body organ, the rarity and heterogeneity of sarcomas make it difficult to diagnose, treat and run a clinical trial resulting in efficient outcomes. The reason, why Soft tissue sarcoma market (STS market) has limited treatmen...

Mar 10, 2020

Soft tissue sarcoma- a rare tumor – accounting for less than 1% of all cancers – has the major unmet need in the form of limited treatment options for patients. Cytotoxic chemotherapy has been the mainstay of therapy for decades. Active drugs such as doxorubicin, ifosfamide, gemcitabine, taxanes, and several othe...